Jazz to Acquire GW Pharmaceuticals for $7.2B

February 4, 2021 Auto Bot Acquire, Jazz, M&A 0

Shots:

  • Jazz to acquire GW Pharmaceuticals for $220/ GW ADS, out of which $200 in cash and $20 in Jazz ordinary shares, making a total deal value $7.2B with a 50% premium over a GW’s closing stock price on Feb 2, 2021. The transaction expected to close in Q2’21
  • The acquisition will expand Jazz’ neuroscience portfolio and expand its footprints with the addition of Epidiolex which is the first and only FDA-approved prescription cannabidiol medicine
  • Apart from Epidiolex, GW’s pipeline includes nabiximol for spasticity associated with MS and spinal cord injury as well as earlier-stage cannabinoid therapies for autism and schizophrenia

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Cannin

The post Jazz to Acquire GW Pharmaceuticals for $7.2B first appeared on PharmaShots.